Acute Coronary SyndromeMPCS-ACSNCT05164601
Prognosis of Treated Acute Coronary Syndrome Patients: a Multicenter Study
An observational study of Acute Coronary Syndrome, run by Xiang Xie at 2 sites in China.
Trial summary
The MPCS-ACS Study (Multicenter Prospective Cohort Study on Acute Coronary Syndrome) is a comprehensive, forward-looking research project designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) who declined coronary artery bypass grafting (CABG) and underwent percutaneous… Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Acute Coronary Syndrome
- How many people
- 22,500 participants
- Where
- 2 sitesChina
- Study dates
- 1 Jun 2016to 31 Dec 2023
- How long will I take part?
- 7 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Acute Coronary Syndrome
Who may be able to join
- Men and women aged between 18 and 79 years.
- Patients diagnosed with Acute Coronary Syndrome (ACS), including Unstable Angina (UA) and Acute Myocardial Infarction (AMI), based on typical clinical symptoms, changes in electrocardiographic (ECG) readings, and elevated cardiac biomarkers.
- Patients who underwent coronary angiography confirming coronary artery stenosis and opted for PCI treatment instead of coronary artery bypass grafting (CABG).
- Patients who are under long-term follow-up.
Who cannot join
- Patients with rheumatic heart disease, valvular heart disease, or congenital heart disease.
- Patients with malignant tumors or hematologic diseases.
- Patients with severe liver or kidney dysfunction or pulmonary heart disease.
- Patients with a life expectancy of less than one year due to terminal illnesses such as advanced cancer or chronic kidney disease requiring dialysis.
- Patients whose health is severely impacted by acute infections.
Trial locations and contacts
2 sites in 1 country.
China2 sites
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 630000
The First Affiliated Hospital of Xinjiang Medicial University
Ürümqi, Xinjiang, 830000
About this study
Official title: A Multicenter, Prospective Cohort Study Evaluating the Prognosis of Patients with Acute Coronary Syndrome
The MPCS-ACS Study (Multicenter Prospective Cohort Study on Acute Coronary Syndrome) is a comprehensive, forward-looking research project designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) who declined coronary artery bypass grafting (CABG) and underwent percutaneous coronary intervention (PCI) instead. Leveraging a multicenter approach, the study aims to collect data from a diverse patient population, thereby enhancing the generalizability and clinical relevance of its findings.
Upon enrollment, detailed information is gathered, including demographic data, clinical history, and key biochemical markers. The study also documents the various medication regimens prescribed during hospitalization to assess their influence on patient outcomes. A key feature of MPCS-ACS is its rigorous follow-up protocol, which involves regularly monitoring patients after discharge to track recovery progress and the occurrence of any subsequent cardiovascular events.
This methodical approach is designed to generate valuable insights into the long-term prognosis of ACS patients treated with PCI, ultimately contributing to the refinement of therapeutic strategies and improving the standard of care across all participating centers.
Read the detailed description
The Multicenter Acute Coronary Syndrome Prognosis Cohort Study (MPCS-ACS) is a comprehensive, longitudinal research initiative designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) across diverse healthcare settings. Conducted in collaboration with multiple hospitals, this study aims to collect and analyze data from ACS patients admitted between June 1, 2016, and May 31, 2021.
The study will gather an extensive range of variables, including therapeutic interventions, biochemical markers relevant to ACS management, as well as key demographic and clinical history data. By analyzing these factors, the study seeks to gain a deeper understanding of ACS treatment practices during the study period and assess their clinical efficacy.
A robust follow-up protocol is a cornerstone of MPCS-ACS, featuring routine evaluations conducted every six to twelve months after patient discharge. Follow-ups will incorporate both in-person visits and telecommunication to accommodate participants unable to return to the hospital. This dual approach is designed to maximize participant retention and ensure high-quality data collection, thereby enhancing the study's validity and impact.
Through its rigorous methodology and collaborative framework, the MPCS-ACS aims to identify key prognostic factors and outcomes for ACS patients. The ultimate goal is to inform the optimization of care strategies and elevate the standards of cardiovascular treatment across diverse healthcare systems.
- Conditions
- Acute Coronary Syndrome
- Being tested
- No Intervention - Observational Only
- Keywords
- Acute Coronary Syndrome, Acute Myocardial Infarction, coronary heart disease, prognosis
- Medical subject headings
- Acute Coronary Syndrome, Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention - Observational OnlyOther
Clinical Follow-Up
| Study group | Role | What they receive |
|---|---|---|
| AMI Patients Cohort | Not described Receives: Other: No Intervention - Observational Only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Death
All-cause mortality, Cardiac mortality
Measured: 10 years
Secondary outcomes (7)
Major adverse cardiovascular events (MACE)
cardiac death, non-fatal myocardial infarction, significant aortic pathologies including aortic dissection and rupture of aortic aneurysms, episodes of unstable angina necessitating medical intervention, hospitalization for acute heart failure classified as Killip Class IV, and revascularization of the target vessel.
Measured: 10 years
Major adverse cardiovascular and cerebrovascular events (MACCE）
cardiac death, non-fatal myocardial infarction, aortic events such as aortic dissection and aortic aneurysm rupture, episodes of unstable angina requiring medical intervention, hospitalization for acute heart failure assessed at Killip Class IV, target vessel revascularization, cerebrovascular events encompassing ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage.
Measured: 10 years
revascularization of the target vesse
Revascularization of the target vessel was performed using percutaneous coronary intervention (PCI).
Measured: 10 years
episodes of unstable angina necessitating medical intervention
Episodes of unstable angina requiring medical intervention were managed with urgent therapeutic measures.
Measured: 10 years
hospitalization for acute heart failure classified as Killip Class IV
hospitalization for acute heart failure classified as Killip Class IV
Measured: 10 years
non-fatal myocardial infarction
non-fatal myocardial infarction
Measured: 10 years
cerebrovascular events
ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2021
- Study start1 Jun 2016
- Primary completion31 May 2021
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 22,500 participants (actual)
- Target duration
- 7 Years
Sponsor and investigators
- Lead sponsor
- Xiang Xie
- Sponsor type
- University, hospital or other
- Collaborators
- Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, The Third Affiliated Hospital of Jinzhou Medical University
- Responsible party
- Sponsor-investigator, Xiang Xie, Xinjiang Medical University
- Investigators
- Xiang Xie, PhD, Principal investigator, Xinjiang Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05164601
- Sponsor's protocol ID
- xx20161107
- Acronym
- MPCS-ACS
- Status last verified
- Jan 2025
- First submitted
- 7 Nov 2018
- Last updated
- 4 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Prospective Cohort Study Evaluating the Prognosis of Patients with Acute Coronary Syndrome
- ClinicalTrials.gov ID
- NCT05164601
- Acronym / sponsor ID
- MPCS-ACS / xx20161107
- Conditions
- Acute Coronary Syndrome
- Keywords
- Acute Coronary Syndrome, Acute Myocardial Infarction, coronary heart disease, prognosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22,500 participants (actual)
- Lead sponsor
- Xiang XieUniversity, hospital or other
- Collaborators
- Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, The Third Affiliated Hospital of Jinzhou Medical University
- Study start
- 1 Jun 2016 (actual)
- Primary completion
- 31 May 2021 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 20 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The MPCS-ACS Study (Multicenter Prospective Cohort Study on Acute Coronary Syndrome) is a comprehensive, forward-looking research project designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) who declined coronary artery bypass grafting (CABG) and underwent percutaneous coronary intervention (PCI) instead. Leveraging a multicenter approach, the study aims to collect data from a diverse patient population, thereby enhancing the generalizability and clinical relevance of its findings.
Upon enrollment, detailed information is gathered, including demographic data, clinical history, and key biochemical markers. The study also documents the various medication regimens prescribed during hospitalization to assess their influence on patient outcomes. A key feature of MPCS-ACS is its rigorous follow-up protocol, which involves regularly monitoring patients after discharge to track recovery progress and the occurrence of any subsequent cardiovascular events.
This methodical approach is designed to generate valuable insights into the long-term prognosis of ACS patients treated with PCI, ultimately contributing to the refinement of therapeutic strategies and improving the standard of care across all participating centers.
Detailed description
The Multicenter Acute Coronary Syndrome Prognosis Cohort Study (MPCS-ACS) is a comprehensive, longitudinal research initiative designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) across diverse healthcare settings. Conducted in collaboration with multiple hospitals, this study aims to collect and analyze data from ACS patients admitted between June 1, 2016, and May 31, 2021.
The study will gather an extensive range of variables, including therapeutic interventions, biochemical markers relevant to ACS management, as well as key demographic and clinical history data. By analyzing these factors, the study seeks to gain a deeper understanding of ACS treatment practices during the study period and assess their clinical efficacy.
A robust follow-up protocol is a cornerstone of MPCS-ACS, featuring routine evaluations conducted every six to twelve months after patient discharge. Follow-ups will incorporate both in-person visits and telecommunication to accommodate participants unable to return to the hospital. This dual approach is designed to maximize participant retention and ensure high-quality data collection, thereby enhancing the study's validity and impact.
Through its rigorous methodology and collaborative framework, the MPCS-ACS aims to identify key prognostic factors and outcomes for ACS patients. The ultimate goal is to inform the optimization of care strategies and elevate the standards of cardiovascular treatment across diverse healthcare systems.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 7 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AMI Patients Cohort | – | Other: No Intervention - Observational Only |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Acute Coronary Syndrome
Key inclusion criteria (4 listed)
- Men and women aged between 18 and 79 years.
- Patients diagnosed with Acute Coronary Syndrome (ACS), including Unstable Angina (UA) and Acute Myocardial Infarction (AMI), based on typical clinical symptoms, changes in electrocardiographic (ECG) readings, and elevated cardiac biomarkers.
- Patients who underwent coronary angiography confirming coronary artery stenosis and opted for PCI treatment instead of coronary artery bypass grafting (CABG).
- Patients who are under long-term follow-up.
Key exclusion criteria (5 listed)
- Patients with rheumatic heart disease, valvular heart disease, or congenital heart disease.
- Patients with malignant tumors or hematologic diseases.
- Patients with severe liver or kidney dysfunction or pulmonary heart disease.
- Patients with a life expectancy of less than one year due to terminal illnesses such as advanced cancer or chronic kidney disease requiring dialysis.
- Patients whose health is severely impacted by acute infections.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention - Observational OnlyClinical Follow-Up | Other | AMI Patients Cohort |
Primary outcome
Death
Time frame: 10 years
All-cause mortality, Cardiac mortality
7 secondary outcomes
Major adverse cardiovascular events (MACE)
Time frame: 10 years
Major adverse cardiovascular and cerebrovascular events (MACCE）
Time frame: 10 years
revascularization of the target vesse
Time frame: 10 years
episodes of unstable angina necessitating medical intervention
Time frame: 10 years
hospitalization for acute heart failure classified as Killip Class IV
Time frame: 10 years
non-fatal myocardial infarction
Time frame: 10 years
cerebrovascular events
Time frame: 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiang Xie, PhD principal investigator
Xinjiang Medical University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by Xiang Xie at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2025.